July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Dynamics of hyperreflective foci shortly after anti-VEGF treatment in neovascular age-related macular degeneration
Author Affiliations & Notes
  • Manuel Hermann
    Center of Ophthalmology, University of Cologne, Koeln, Germany
  • Vasilena Sitnilska
    Center of Ophthalmology, University of Cologne, Koeln, Germany
  • Philip Enders
    Center of Ophthalmology, University of Cologne, Koeln, Germany
  • Sascha Fauser
    Center of Ophthalmology, University of Cologne, Koeln, Germany
  • Lebriz Altay
    Center of Ophthalmology, University of Cologne, Koeln, Germany
  • Footnotes
    Commercial Relationships   Manuel Hermann, None; Vasilena Sitnilska, None; Philip Enders, None; Sascha Fauser, Genentech (C), Roche Pharmaceuticals (E); Lebriz Altay, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3232. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Manuel Hermann, Vasilena Sitnilska, Philip Enders, Sascha Fauser, Lebriz Altay; Dynamics of hyperreflective foci shortly after anti-VEGF treatment in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3232.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the dynamics of hyperreflective foci (HF) in the first three weeks following injection of anti-VEGF agents for neovascular age-related macular degeneration (nAMD).

Methods : This study is a post-hoc analysis of the prospective observational study EIFU (Early intensified follow-up) performed at the Center of Ophthalmology of the University of Cologne (German Clinical Trial Register DRKS00010061). This study included 47 patients with active choroidal neovascularization secondary to nAMD treated with anti-VEGF (vascular endothelial growth factor). Spectral-domain optical coherence tomography (Spectralis OCT, Heidelberg Instruments) was performed at baseline (before treatment) and one, two and three weeks after treatment. The absolute number of HF was assessed for each measurement within the 3000 µm grid in outer nuclear layers and in photoreceptor complex employing a standardized protocol with repeated measurements by multiple observers. Statistical analysis was based on repeated measures analysis of variance (rmANOVA) followed by post-hoc paired samples t-tests (IBM SPSS 23).

Results : Complete data sets could be obtained from 45 patients (mean age 76.0 ± 7.0 years, 28 female). The rmANOVA revealed a significant effect of therapy (F(3,132)=9.9; p<0.00001). Post hoc paired samples t-tests showed a statistically significant drop of mean HF from baseline (25.93 ± 21.5) to week one (19.0 ± 15.0) (p=0.003) which remained significant at week two (18.5 ± 16.4) and week three (16.5 ± 14.0) (both p<0.001). However the further drop of mean HF after week 1 did not reach statistical significance (all p >0.1).

Conclusions : This study describes the rapid dynamics of HF in nAMD within the first week after VEGF suppression in nAMD-patients. Our data suggest that HF could be a useful non-invasive imaging biomarker reflecting inflammatory disease activity.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×